Online platform to check for prostate cancer risk | CUH

Skip to main content Accessibility tools British Sign Language (BSL) Communication support Translation services Menu Visiting our hospitals

Your visit

Your appointment Travel and parking Finding your way around CUH Directions – mobile app Visiting a patient Your stay with us Covid-19 vaccine What to expect when you come to our hospitals Carers Waiting times Overseas and paying patients Shops, cafés and restaurants The Rosie Hospital Maps and directions Maternity Rosie birth centre About the Rosie Research at the Rosie

Helping families and friends share messages and photographs with patients in our hospitals.

Services

Our services A-Z

Emergency department Cancer services Cardiology (Heart) Children's services (Paediatrics) Ear, nose and throat Endoscopy Imaging (Radiology) Community Diagnostic Centres Outpatients Clinics A-Z Wards A-Z Patient information Video consultation appointments The Rosie Hospital Rosie services, clinics and wards Rosie patient information and videos

MyChart - Keeping you involved and informed about your care.

Research

Our research

Our facilities Contact Research East of England Secure Data Environment Get involved Conducting research at CUH Clinical trials Take part in research Research for nurses, midwives and AHPs Research document library About us

About CUH

Vision and values Our Strategy - CUH Together 2025 Addenbrooke's 3 - CUH modernisation programme Climate emergency - our response Equality, diversity, inclusion Our structure Board of directors Governors Foundation Trust Membership Our hospitals Our people Staff directory Our history Reports and publications Annual report and accounts Quality plan and reports Quality, assurance and performance Patient Safety Incident Response Framework (PSIRF) News Events ACT - Charity

Our strategy for a healthier life for everyone through care, learning and research

Working for us

Join our exceptional team

Current vacancies Contact CUH Careers New starters Working with us Where could I work? Apprenticeships

Take a look at our latest career opportunities

Contact

Contact us

Let us know your views Talk to us Say thank you Make a complaint Surveys How to get involved Acting on feedback Surveys You made a difference awards Patient Advice and Liaison Service (PALS) How would you like us to communicate with you? Covid-19 vaccine Contact enquiries Media enquiries

Contact us - Commonly asked questions

Mobile menu open

Visiting our hospitals Back Visiting our hospitals Your appointment Travel and parking Finding your way around Back Finding your way around CUH Directions – mobile app Visiting a patient Your stay with us Covid-19 vaccine What to expect when you come to our hospitals Carers Waiting times Overseas and paying patients Shops, cafés and restaurants The Rosie Hospital Back The Rosie Hospital Maps and directions Maternity Rosie birth centre About the Rosie Research at the Rosie Services Back Services Emergency department Cancer services Cardiology (Heart) Children's services (Paediatrics) Ear, nose and throat Endoscopy Imaging (Radiology) Community Diagnostic Centres Outpatients Clinics A-Z Wards A-Z Patient information Video consultation appointments The Rosie Hospital Back The Rosie Hospital Rosie services, clinics and wards Rosie patient information and videos Research Back Research Our facilities Contact Research East of England Secure Data Environment Get involved Back Get involved Conducting research at CUH Clinical trials Take part in research Research for nurses, midwives and AHPs Research document library About us Back About us Vision and values Back Vision and values Our Strategy - CUH Together 2025 Addenbrooke's 3 - CUH modernisation programme Climate emergency - our response Equality, diversity, inclusion Our structure Back Our structure Board of directors Governors Foundation Trust Membership Our hospitals Back Our hospitals Our people Staff directory Our history Reports and publications Back Reports and publications Annual report and accounts Quality plan and reports Quality, assurance and performance Patient Safety Incident Response Framework (PSIRF) News Events ACT - Charity Working for us Back Working for us Current vacancies Contact CUH Careers New starters Working with us Where could I work? Apprenticeships Contact Back Contact Let us know your views Back Let us know your views Talk to us Say thank you Make a complaint Surveys How to get involved Acting on feedback Surveys You made a difference awards Patient Advice and Liaison Service (PALS) How would you like us to communicate with you? Covid-19 vaccine Contact enquiries Media enquiries Accessibility tools British Sign Language (BSL) Communication support Translation services Home Back to News Online platform to check for prostate cancer risk

Online platform to check for prostate cancer risk

Print this page 09 Dec 2022 4 min read

Cambridge scientists have created an online tool for predicting an individual’s risk of developing prostate cancer, to enable more targeted testing, treatment and early diagnosis.

CanRisk-Prostate, developed by researchers at the University of Cambridge and The Institute of Cancer Research, London, will be incorporated into the group’s CanRisk web tool (opens in a new tab) , which has now recorded almost 1.2 million risk predictions.

The free tool is already used by healthcare professionals worldwide to help predict the risk of developing breast and ovarian cancers.

This research on powerful, user-friendly, web-based prediction tools for patients and clinicians to detect cancer earlier, will form part of the work at the Early Cancer Institute Research Clinic, embedded within the new Cambridge Cancer Research Hospital.

Prostate cancer awareness blue ribbon

Testing for prostate cancer

Prostate cancer is the most common type of cancer in men. According to Cancer Research UK, over 52,000 men are diagnosed with the disease each year and there are more than 12,000 deaths.

Over three-quarters (78%) of men diagnosed with prostate cancer survive for over ten years, but this proportion has barely changed over the past decade in the UK.

Testing for prostate cancer involves a blood test that looks for a protein known as a prostate-specific antigen (PSA) that is made only by the prostate gland; however, it is not always accurate.

According to the NHS website, around three in four men with a raised PSA level will not have cancer. Further tests, such as tissue biopsies or MRI scans, are therefore required to confirm a diagnosis.

For the first time, it combines information on the genetic makeup and prostate cancer family history, the main risk factors for the disease, to provide personalised cancer risks.

Professor Antonis Antoniou Antonis Antoniou, Professor of Cancer Risk, University of Cambridge

Professor Antonis Antoniou from the Department of Public Health and Primary Care at the University of Cambridge said:

“Prostate cancer is the most common cancer in men in the UK, but population-wide screening based on PSA isn’t an option: these tests are often falsely positive, which means that many men would then be biopsied unnecessarily.

Also, many prostate tumours identified by PSA tests are slow-growing and would not have been life-threatening. The treatment of these tumours may do more harm than good.

“What we need is a way of identifying those men who are at greatest risk, allowing us to target screening and diagnostic tests where they are most needed, while also reducing the harms for those men who have low risk of the disease. This is what CanRisk-Prostate aims to do.

Predicting cancer risk

Prostate cancer is one of the most genetically determined of common cancers. Inherited faulty versions of the BRCA2, HOXB13 and possibly BRCA1 genes are associated with moderate-to-high risk of prostate cancer, though such faults are rare in the population.

Writing in the Journal of Clinical Oncology, the researchers – supported by Cancer Research UK – describe the development of the first comprehensive prostate cancer model using genetic and cancer family history data from almost 17,000 families affected by prostate cancer.

One in six men (16%) will develop prostate cancer by the time they are 85 years old. Using the model, the team found that the predicted risk was higher for men who had a father diagnosed with prostate cancer – 27% if the father was diagnosed at an older age (80 years), but as high as 42% if the father was diagnosed at a young age (50 years).

In practice, say the researchers, clinicians will be able to use any combination of cancer family history, rare and common genetic variants to provide a personalised risk.

We’ve created the most comprehensive tool to date for predicting a man’s risk of developing prostate cancer.

Dr Tommy Nyberg

Dr Tommy Nyberg from the MRC Biostatistics Unit at Cambridge said:

“We hope this will help clinicians and genetic counsellors assess their clients’ risk and provide the appropriate follow-up.

“Over the next 12 months, we aim to build this tool into the widely used CanRisk tool, which will facilitate the risk-based clinical management of men seen in family cancer clinics and enable risk-adapted early detection approaches to the population at large.”

Professor Ros Eeles from The Institute of Cancer Research, London and co-author on the study said:

“This is an important step forward as it will enable clinicians to have conversations with men about their individual risk of prostate cancer based on the most accurate computer model to date. This will help them in making decisions about screening.”

So far, the data used to develop CanRisk-Prostate has been from men of European ancestry. The team hope to be able to include data from men of other ethnicities as further research is undertaken.

The Early Cancer Institute at the University of Cambridge. Picture: Lloyd Mann

The University of Cambridge recently launched the Early Cancer Institute (opens in a new tab) with the aim of detecting cancer early enough to cure it.

It is the first physical institute in the UK dedicated to early cancer. The new Cambridge Cancer Research Hospital (opens in a new tab) is also planned for the near future, bringing together clinical and research expertise in a new, world-class hospital, designed in partnership with patients.

There is also an Early Detection and Diagnosis centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust where a prostate risk clinic has been established to translate these findings into targeted screening programmes.

The research was supported by the Cancer Research UK-funded CanRisk programme. Additional support for CanRisk-Prostate was provided by Prostate Cancer UK, The Institute of Cancer Research, Everyman Campaign, National Cancer Research Network UK, National Cancer Research Institute, NIHR Cambridge Biomedical Research Centre and the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

Reference

Nyberg, T et al. CanRisk-Prostate: a comprehensive, externally validated risk model for the prediction of future prostate cancer. Journal of Clinical Oncology; 9 Dec 2022; Link to paper here: https://doi.org/10.1200/JCO.22.01453 (opens in a new tab)

Share this content

Related news & stories

View all

Making prostate cancer diagnosis simple, safe and affordable

This document was correct at the time of printing - 30-10-2024 18:58

Together Safe Kind Excellent

Visiting our hospitals Our services A-Z Our research Equality, diversity, inclusion Healthcare professionals MyChart New starters

Contact us

Cambridge University Hospitals 
NHS Foundation Trust
Hills Road, Cambridge
CB2 0QQ

Telephone 01223 805000

Telephone 01223 245151

Contact us

Connect with us

Donate today Careers GP Portal Accessibility statement Back Accessibility statement Recite Me digital accessibility user guide Video transcripts Privacy Back Privacy Patient privacy notice Records retention, destruction and archive Back Records retention, destruction and archive Trust retention and destruction schedule Website privacy Back Website privacy Social media house rules Cookies E-mail disclaimer Our agreement with Arcturis

© 2024 Cambridge University Hospitals

---

Posted by Jack Read more Comments (15) 2024.10.30 19:57